Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-865-4
CAS number: 111-40-0
Two chronic dermal studies (one key, one supporting) in male C3H/HeJ Mice were conducted to determine the potential of diethylene triamine (DETA) to cause skin tumors. Both high purity and commercial grade were used in these evaluations.
Diethylene triamine is not carcinogenic via the dermal route and not
classifiable under GHS.
Male C3H/HeJ mice were administerd 25 ul of a 5% solution of DETA three
times per week throughout their lifetime. The Mean Survival time was 587
and 662 days for the purified and commercial grade DETA. There were no
treatment related tumors of the skin in any of the mice. Gross
pathology and histologic analysis of kidney, urinary bladder, stomach,
liver, skin, thyroids, adrenals, heart, spleen, mesenteric lymph node,
bronchi lymph node, pancreatic lymph node, mediastinum, lung prostate,
and seminal vesicles did not show any treatment related tumors.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Sellel veebilehel kasutatakse küpsiseid, et tagada lehe parim kasutus.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again